Lococo Filippo, Nachira Dania, Chiappetta Marco, Sperduti Isabella, Congedo Maria Teresa, Meacci Elisa, Leoncini Fausto, Trisolini Rocco, Crisci Roberto, Curcio Carlo, Casiraghi Monica, Margaritora Stefano
Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
J Clin Med. 2023 Mar 17;12(6):2345. doi: 10.3390/jcm12062345.
Since no robust data are available on the real rate of unforeseen N1-N2 disease (uN) and the relative predictive factors in clinical-N0 NSCLC with peripheral tumours > 3 cm, the usefulness of performing a (mini)invasive mediastinal staging in this setting is debated. Herein, we investigated these issues in a nationwide database. From 01/2014 to 06/2020, 15,784 thoracoscopic major lung resections were prospectively recorded in the "Italian VATS-Group" database. Among them, 1982 clinical-N0 peripheral solid-type NSCLC > 3 cm were identified, and information was retrospectively reviewed. A mean comparison of more than two groups was made by ANOVA (Bonferroni correction for multiple comparisons), while associations between the categorical variables were estimated with a Chi-square test. The multivariate logistic regression model and Kaplan-Meyer method were used to identify the independent predictors of nodal upstaging and survival results, respectively. At pathological staging, 229 patients had N1-involvement (11.6%), and 169 had uN2 disease (8.5%). Independent predictors of uN1 were SUVmax (OR: 1.98; CI 95: 1.44-2.73, = 0.0001) and tumour-size (OR: 1.52; CI: 1.11-2.10, = 0.01), while independent predictors of uN2 were age (OR: 0.98; CI 95: 0.96-0.99, = 0.039), histology (OR: 0.48; CI 95: 0.30-0.78, = 0.003), SUVmax (OR: 2.07; CI 95: 1.15-3.72, = 0.015), and the number of resected lymph nodes (OR: 1.03; CI 95: 1.01-1.05, = 0.002). The unforeseen N1-N2 disease in cN0/NSCLCs > 3 cm undergoing VATS resection is observable in between 12 and 8% of all cases. We have identified predictors that could guide physicians in selecting the best candidate for (mini)invasive mediastinal staging.
由于目前尚无关于意外N1-N2期疾病(uN)的实际发生率以及外周肿瘤>3cm的临床N0期非小细胞肺癌(NSCLC)相关预测因素的可靠数据,因此对于在此种情况下进行(微创)纵隔分期的实用性存在争议。在此,我们在一个全国性数据库中对这些问题进行了研究。2014年1月至2020年6月期间,“意大利VATS组”数据库前瞻性记录了15784例胸腔镜下肺大切除术。其中,1982例为临床N0期外周实性型NSCLC且肿瘤>3cm,对这些病例的信息进行了回顾性分析。多组均值比较采用方差分析(多重比较采用Bonferroni校正),分类变量之间的相关性采用卡方检验进行评估。多因素逻辑回归模型和Kaplan-Meyer方法分别用于确定淋巴结分期上调和生存结果的独立预测因素。在病理分期时,229例患者有N1期受累(11.6%),169例有意外N2期疾病(8.5%)。意外N1期的独立预测因素为最大标准摄取值(SUVmax)(比值比:1.98;95%置信区间:1.44-2.73,P=0.0001)和肿瘤大小(比值比:1.52;置信区间:1.11-2.10,P=0.01),而意外N2期的独立预测因素为年龄(比值比:0.98;95%置信区间:0.96-0.99,P=0.039)、组织学类型(比值比:0.48;95%置信区间:0.30-0.78,P=0.003)、SUVmax(比值比:2.07;95%置信区间:1.15-3.72,P=0.015)以及切除淋巴结数量(比值比:1.03;95%置信区间:1.01-1.05,P=0.002)。接受VATS切除的cN0/NSCLCs>3cm患者中,意外N1-N2期疾病在所有病例中的发生率在12%至8%之间。我们已经确定了一些预测因素,可指导医生选择(微创)纵隔分期的最佳候选患者。